@arstechnica the problem with these preliminary results is not that the study itself is in any way questionable, but that the drug company is doing hundreds of these studies for all of their drugs hoping to find one that helps -- if they find one with results 1% chance to be random and they've done 100 trials... Nothing wrong with this but that's the context to understand why preliminary results shouldn't be reported like this.
@arstechnica When the initial reports on this came out a year ago, I tried azelastine nasal spray. I am allergy prone and it's cheap so why not. I had some annoying effects such as nosebleeds, so I switched to oral loratadine. According to the initial paper, loratadine has the same benefit as azelastine - there's a whole family of similar antihistamines. No way to know if it has helped protect me from COVID but it probably did prevent my usual springtime hay fever.
@arstechnica
- the intendwd treatment was azelastine nasal spray three times per day.
- "In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]) (OR, 0.31; 95% CI, 0.11-0.87)."
- https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2838335

#science #covid #healthcare #medicine #research